Therapeutic Advances in Gastroenterology · 2009 · 60 citations · 50 references
MedicinePharmacologyPharmacotherapyGastroenterologyInflammationMucosal ImmunologyAnti-inflammatory PharmacologyGastrointestinal InflammationInflammatory Bowel DiseaseInflammatory Bowel Disease CareInflammatory Disease PharmacotherapyUlcerative Colitis PharmacotherapyBiologic Therapy ManagementChronic ColitisClinical RemissionFish Oil SupplementationInflammatory Bowel Disease TherapyTreatment StrategiesTumor Necrosis Factor TherapyUlcerative Colitis Pathology
Ulcerative colitis (UC) is a disease of unknown etiology characterized by inflammation of the mucosa and occasionally the submucosa of the colon. Conventional drug therapy for UC involves use of aminosalicylates, corticosteroids, azathioprine/6-mercaptopurine, cyclosporine and anti-tumor necrosis factor therapy. Alternative therapies include probiotics, nicotine and fish oil. Drugs like tacrolimus, rosiglitazone and Trichuris suis ova are being evaluated for use in UC patients. With the new biologic agents, new treatment options for UC continue to evolve. In this article we will discuss the conventional drugs, the alternative therapies and the management strategies according to the severity and extent of UC.
50
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Simon Lichtiger, D. H. Present, Asher Kornbluth et al. · New England Journal of Medicine · 1994 · 1.7K citations